Universal reference book for medicines
Product name: ADENOCIN (ADENOCIN)

Active substance: comb.
drug
Type: Cardiotonics with cardioprotective action

Manufacturer: EGV-PHARMA (Russia) manufactured by BIOTECHFARM GE (Georgia)
Composition, form of production and packaging
Lyophilizate for solution preparation for
intravenous and intravenous administration 1 amp.

Inosine 80 mg

α-acetyl-digoxin 75 μg

nadide 500 mcg

oxyfedrin 300 mcg

ampoules (5) - packs of cardboard.

ampoules (10) - packs of cardboard.

ampoules (20) - packs of cardboard.

bottles (5) - packs cardboard.

bottles (10) - packs of cardboard.

bottles (20) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2010.

PHARMACHOLOGIC EFFECT

Adenocin is a cardiotonic agent with a cardioprotective effect, the ability to suppress three key links of the systemic inflammatory response syndrome: endotoxemia, tissue hypoxia and dysfunction of the body's own defense systems.
Adenocin stimulates the synthesis of ATP in the cell itself by disinhibiting glycolysis, stimulating the activity of the tricarboxylic acid cycle and, as a consequence, transporting electrons to oxygen. As a result, Adenocin eliminates the energy-deficient state of the cell, not only in conditions of rest, but also with increased stress on the heart. It has a direct stimulating effect on the contractile and relaxation functions of the myocardium and restores the transport of calcium ions through the membranes of the cardiomyocyte. Adenocin significantly reduces the severity of stagnant phenomena in the large and small circle of blood circulation, reduces end-diastolic pressure, restores or significantly improves the parameters of central hemodynamics and heart geometry, reduces the degree of pulmonary hypertension and general peripheral vascular resistance. Reduces the need for myocardium in oxygen, overcomes the refractoriness of the myocardium to medication, even in severe forms of heart failure caused by non-coronary heart disease and cardiosclerosis. The drug has a vasodilating effect, improves microcirculation and collateral blood supply, enhances diuresis. Prevents and removes coronary spasm, thins heart rate to normal and stabilizes blood pressure.
PHARMACOKINETICS

With intravenous administration, the bioavailability of the main active ingredient (NAD) averages 85% (70-95%).
The time to reach the maximum concentration is 10-18 minutes. after the introduction of 2 vials (ampoules) of adenocin. The greatest part of the dose is excreted in the first 4.5 hours after administration and is completely eliminated within 8 hours. T 1/2 is an average of 3.8 hours. It penetrates the blood-brain barrier. If the kidney function is impaired (a decrease in creatinine clearance, 30-60 ml / min) toxic concentrations in the body are not achieved. It is excreted mainly by the kidneys.
INDICATIONS

Adenocin is indicated for use in complex therapy:

- Chronic heart failure caused by non-coronary heart disease (myocarditis, dilated cardiomyopathy, cardiosclerosis), postinfarction cardiosclerosis, chronic ischemic heart disease;

- Chronic heart failure after heart surgery and in preparation for heart transplantation, combined and isolated mitral and aortic defects;

- ischemic cardiomyopathy,

- cardiopulmonary insufficiency,

- tahisistolicheskoy form of atrial fibrillation,

- paroxysmal ventricular and supraventricular tachycardia,

- the drug can be used in cases where therapeutic doses of cardiac glycosides lead to the development of glycosidic intoxication.

DOSING MODE

Intravenous and intramuscular!

Intravenous drip: dissolve the contents of 1-2 vials (ampoules) of Adenocin in 70-100 ml of 5% dextrose (glucose) or saline (with diabetes) and inject one or two times / day for 1 hour.
The maximum daily dose of up to 4 vials (ampoules) in 100 ml of 5% dextrose (glucose) two times a day, maintaining the dose for stabilizing the condition (reducing symptoms of CHF and improving central hemodynamics) 1-2 vials (ampoules) intramuscularly in 5 ml of water for injections.
Intravenous bolus (very slowly): 1 to 2 vials (ampoules) of Adenocin diluted in 15-20 ml of 5% dextrose (glucose) or saline and administered for 15-20 minutes once or twice a day.
The maximum daily dose of up to 4 vials (ampoules). Intramuscularly: administer the contents of 1-2 vials (ampoules) of Adenocin dissolved in 5 ml of water for injection, 1-3 times / day. The maximum daily dose of 8 vials (ampoules).
The course of treatment 10-40 days, depending on the severity of the disease, the severity of symptoms of chronic heart failure and the patient's response to ongoing therapy.

Repeat courses are recommended to be conducted at least 6 months later, with CHF III-IV functional class for NYHA in 3 months.

SIDE EFFECT

Allergic reactions are possible.

CONTRAINDICATIONS

- pregnancy and lactation;

- age up to 18 years;

- Hypersensitivity to the drug.

With caution: with severe renal failure, creatinine clearance less than 30 ml / min (clinical experience is limited), with simultaneous therapy with cardiac glycosides, cardiotonic drugs, antiarrhythmics.

PREGNANCY AND LACTATION

Contraindicated during pregnancy and lactation.

APPLICATION FOR FUNCTIONS OF THE LIVER

With caution: with severe renal failure, creatinine clearance less than 30 ml / min (experience in clinical use is limited).

APPLICATION FOR CHILDREN

Contraindicated in children under 18 years.

SPECIAL INSTRUCTIONS

With simultaneous use with cardiac glycosides and other cardiotonic drugs, antiarrhythmics and with malignant hypertension, it is necessary to monitor heart rate, blood pressure and ECG.

OVERDOSE

There is no information.

DRUG INTERACTION

Possible simultaneous therapy with nitrates (in various dosage forms), including prolonged action, as well as anticoagulants, diuretics, hypoglycemic agents for ingestion and / insulin, blockers of "slow" calcium channels, including nimodipine, beta adrenoblockers, inhibitors angiotensin-converting enzyme and other antihypertensive agents, lipid-lowering agents, nonsteroidal anti-inflammatory drugs and antibacterial agents of various
Lassa gliatilin, potassium orotate, potassium chloride, prednisolone, analgesics, antihistamines, nootropics. Simultaneous use with cardiotonic drugs (dopamine, dobutamine), as well as antiarrhythmics only for special indications. With simultaneous use with antihypertensive drugs, diuretics may increase their effect.
TERMS OF RELEASE FROM PHARMACY

On prescription.

TERMS AND CONDITIONS OF STORAGE

In a dry, protected from light and out of reach of children, at a temperature of 0 ° C to 10 ° C.
Shelf life - 3 years.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!